Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.29 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: bimagrumab, dibotermin alfa | 0.81 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 222 | 0.91 |
| pathways Reactome | 4 pathways; mostly growth signalling | 0.60 |
No case: the score is under the bar. Receipt 1368
Sealed predictions
- ACVR2B in dopamine neurons, braak-0.32 (p 0.400) → -0.60 (p 0.090)receipt 1374
Swarm cases
receipt 1374: ACVR2B in dopamine neurons, braak
- power
- full sample -0.51 (p 0.029, n 18), 95% CI -0.79 to -0.06. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: -0.50 (p 0.035, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.59 (p 0.010, n 18). not the mix.
- skeptic
- leave-one-out range -0.62 to -0.45, sign flips 0; without severely affected donors -0.51 (p 0.029, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ACVR2B in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts